Ondansetron Eugia (Ondansetron)

Ondansetron Eugia is a selective 5‑HT3 receptor antagonist that is used to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: helps maintain patient comfort during and after treatment.
• Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be considered when conventional therapy fails.

• Ondansetron blocks the serotonin 5‑HT3 receptors located in the chemoreceptor trigger zone, vagal afferents of the gastrointestinal tract and the central nervous system. By inhibiting this receptor, it prevents serotonin‑mediated activation of the vomiting centre, thereby reducing the initiation of nausea and vomiting signals.

Side effects reported with ondansetron are generally mild to moderate and vary with the route of administration.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel habit changes.
• Diarrhoea: transient loose stools.
• Fatigue: feeling of tiredness.
• Dizziness: light‑headed sensations.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with intravenous use.
• Severe hypersensitivity: rash, pruritus, angio‑edema or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Seizures: infrequent but reported in high‑dose intravenous administration.

When prescribing ondansetron, clinicians should consider patient‑specific factors and follow safe handling practices.

• Cardiac assessment: obtain baseline ECG in patients with known cardiac disease or electrolyte abnormalities.
• Electrolyte monitoring: correct hypokalaemia, hypomagnesaemia or hypocalcaemia before use.
• Drug‑interaction review: evaluate concomitant medications that may affect QT interval.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Renal/hepatic impairment: dose adjustment may be required in severe dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several drug classes, altering its safety profile or efficacy.

Major Interactions (Avoid)

• Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): increase risk of QT prolongation.
• Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation.

Moderate Interactions (Monitor Closely)

• Serotonergic agents (e.g., SSRIs, tramadol, linezolid): potential for serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP2D6 substrates (e.g., metoprolol, codeine): ondansetron can inhibit metabolism, increasing exposure.
• Oral contraceptives: may reduce hormonal efficacy.
• Antacids containing aluminium or magnesium: may decrease oral absorption if taken simultaneously.